TICKERNERD
Menu
PACSPACSHealthcare · Medical Care Facilities

PACS Stock Forecast: PACS Group, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$44
0.00% on the day

The 6 Wall Street analysts covering PACS Group, Inc. hold a median 12-month price target of $60 — +35.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$7.0B
Ticker Nerd rank
93 / 100
Median analyst target
$60
Analysts covering
6
Total return, dividends reinvested
1W
−0.2%
1M
−5.5%
YTD
+15.3%
1Y
+267.2%
From 52W high
−8.7%
From 52W low
+473.9%
$8
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PACS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores PACS Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
96
Revisions
92
Growth
86
Issuance
83
Value
67
Accruals
63
Volatility
59
Quality
43
Size
20

Momentum (96): The shares have been drifting up relative to others.

Quality (43): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Size (20): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PACS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PACS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26PACSHigh $62Median $60Low $57

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $57Median $60High $62

The green dot is the last close — the median target sits +35.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
10 Aug 2026OppenheimerMaintainsOutperform$48 → $57
6 Aug 2026RBC CapitalMaintainsOutperform$52 → $57
6 Aug 2026Truist SecuritiesMaintainsBuy$52 → $62
6 Aug 2026UBSMaintainsBuy$57 → $60
8 July 2026UBSMaintainsBuy—
8 July 2026UBSMaintainsBuy$50 → $57
18 May 2026Truist SecuritiesMaintainsBuy—
13 May 2026OppenheimerMaintainsOutperform—
4 Mar 2026OppenheimerMaintainsOutperform—
4 Mar 2026UBSMaintainsBuy—
27 Feb 2026RBC CapitalMaintainsOutperform—
18 Dec 2025UBSReinstatesBuy$50 → $42
17 Dec 2025JP MorganReinstatesOverweight$44
20 Nov 2025RBC CapitalMaintainsOutperform—
6 Jan 2025MacquarieMaintainsOutperform—
6 Jan 2025Truist SecuritiesMaintainsBuy—
17 Dec 2024JP MorganDowngradeNeutral—
18 Nov 2024Stephens & Co.MaintainsOverweight—
6 Nov 2024JP MorganReinstatesOverweight$40
14 Oct 2024Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PACS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

PACS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+19.8%
Analysts raising
4
Analysts cutting
0
Fundamentals

PACS Group, Inc. (PACS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.9×

Cheaper than 30% of US stocks

Price / sales
1.3×

Cheaper than 65% of US stocks

Price / book
6.3×

Cheaper than 17% of US stocks

EV / EBITDA
21.4×

Cheaper than 14% of US stocks

Growth & margins
Revenue growth (YoY)
9.1%

Higher than 50% of US stocks

Earnings growth (YoY)
49.9%

Higher than 75% of US stocks

Gross margin
17.1%

Higher than 17% of US stocks

Operating margin
7.7%

Higher than 60% of US stocks

Net margin
4.8%

Higher than 59% of US stocks

Returns & dividend
Return on equity
27.9%

Higher than 87% of US stocks

Return on assets
4.6%

Higher than 74% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PACS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
PACSPACS Group, Inc.$7.0B
93
CHEChemed Corp.$7.3B
89
LFSTLifestance Health Group, Inc.$4.8B
96
ENSGThe Ensign Group, Inc.$10.4B
67
UHSUniversal Health Services, Inc.$10.4B
66
CONConcentra Group Holdings Parent, Inc.$4.5B
95
DVADaVita, Inc.$11.6B
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own PACS Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PACS news & analysis

3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage

Zacks Investment Research · 24 Aug 2026positive

Zacks Investment Research identified CareDx, BrightSpring, and PACS Group as medical service stocks positioned for growth as digital health expands and persistent workforce shortages reshape the medical services sector. The article highlights PACS Group among these resilient companies.

Why it matters — For a PACS watcher, this signals that the company is being recognized by analysts as well-positioned within the medical services sector amid ongoing workforce challenges and digital health growth.

Amid Legal Risks, This Company Is Still Rated a Buy

MarketBeat · 19 Aug 2026neutral

MarketBeat reports that despite legal risks, the company retains a Buy rating. The article frames the company within the broader theme of investors seeking stocks that benefit from the aging of the U.S. population, alongside hospital chains, pharmacy benefit managers, and healthcare REITs.

Why it matters — A PACS watcher would care because the piece highlights the company's positioning in the aging-population investment theme while acknowledging ongoing legal risks that could affect the stock.

Wall Street Analysts See a 25.73% Upside in PACS Group, Inc. (PACS): Can the Stock Really Move This High?

Zacks Investment Research · 13 Aug 2026neutral

Zacks Investment Research reported that the consensus price target for PACS Group, Inc. suggests a 25.73% upside potential, while noting that such price targets are not highly effective indicators. The article added that an upward trend in earnings estimate revisions could point to near-term upside for the stock.

Why it matters — PACS watchers would care because analyst price targets and earnings estimate revisions are commonly followed indicators that can influence market sentiment around the stock.

PACS Group Q2 Earnings Call Highlights

MarketBeat · 9 Aug 2026positive

PACS Group reported second-quarter 2026 revenue growth of 9.1% and adjusted EBITDA growth of 25% year over year, citing higher occupancy, an improved skilled nursing patient mix, and continued progress as acquired facilities mature within its operating model.

Why it matters — The results indicate strengthening operational performance across PACS's acquired skilled nursing facilities, which is a key factor for watchers tracking the company's growth trajectory.

PACS Group, Inc. (PACS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

PACS Group, Inc. held its Q2 2026 earnings call, and a transcript of the call has been published on Seeking Alpha. The transcript covers the company's second-quarter 2026 results discussion.

Why it matters — A PACS watcher would want to review the Q2 2026 earnings call transcript to see management's commentary on the company's results and outlook.

FAQ

Frequently asked questions about PACS stock

What is the PACS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering PACS Group, Inc. have a median 12-month price target of $60, with estimates ranging from $57 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PACS stock a buy right now?

Of the 6 analysts covering PACS Group, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PACS Group, Inc. 93 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PACS?

As at 22 Aug 2026, PACS Group, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).

Will PACS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +35.6% from the last close, and Ticker Nerd's factor model ranks PACS Group, Inc. 93 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PACS stock forecast for 2030?

No analyst covering PACS Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PACS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $57 to $62 over the next 12 months.

How has PACS stock performed over the past year?

PACS Group, Inc. returned +267.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does PACS Group, Inc. do?

PACS Group Inc. is a holding company operating a national platform of post-acute care and senior living facilities across 17 states.

What is the latest news on PACS?

The most recent item we track (Zacks Investment Research, 24 Aug 2026): "3 Medical Service Stocks Resilient Amid Persistent Workforce Shortage". Zacks Investment Research identified CareDx, BrightSpring, and PACS Group as medical service stocks positioned for growth as digital health expands and persistent workforce shortages reshape the medical services sector. The article highlights PACS Group among these resilient companies.

Company

About PACS Group, Inc.

PACS Group Inc. is a holding company operating a national platform of post-acute care and senior living facilities across 17 states. The company provides skilled nursing care, assisted living, independent living, and related healthcare services through a portfolio of over 300 independently operated facilities. PACS serves patients and residents recovering from acute medical conditions, illnesses, or serious procedures who require additional care following hospital discharge. Beyond direct facility operations, the company delivers comprehensive support services to its affiliated providers, including administrative services, technology solutions, training programs, and compliance support. Founded in 2013 and headquartered in Salt Lake City, Utah, PACS operates an entrepreneurial model that balances centralized resources with local operational autonomy. The platform supports tens of thousands of daily patients and residents through a network of dedicated healthcare professionals, positioning itself as a significant player in the post-acute care sector.

CEO Mr. Jason Murray · 47,455 employees · United States · https://pacs.com